MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) indication : adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active PsA who have responded inadequately to, or are intolerant to one or more DMARD.

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, August 2018
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Antirheumatic Agents / Therapeutic Use Canada Cost-benefit Analysis Arthritis, Psoriatic / Drug Therapy Dermatologic Agents / Economics
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK539325
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active PsA who have responded inadequately to, or are intolerant to one or more DMARD.
Item Description:	"Final"
Physical Description:	1 PDF file (8 pages)